Entrada Therapeutics Inc(TRDA)
$5.44+0.19 (+3.62%)
TRDA
Entrada Therapeutics Inc financials statements
$5.44
At close:+0.19 (+3.62%)
Want to see TRDA full AI Analyst Report?
Entrada Therapeutics Inc (TRDA) Ratios
164 Followers
Entrada Therapeutics Inc Ratios
TRDA's free cash flow for Q3 2026 was $-30.13M. For the 2026 fiscal year, TRDA's free cash flow was decreased by $-161.00K and operating cash flow was $-29.96M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 12.53 | 11.15 | 2.33 | 9.55 | 44.46 |
| Quick Ratio | 12.53 | 11.15 | 2.33 | 9.55 | 44.46 |
| Cash Ratio | 3.70 | 2.56 | 0.43 | 2.06 | 43.32 |
| Solvency Ratio | -1.96 | 0.71 | -0.02 | -2.35 | -7.03 |
| Operating Cash Flow Ratio | -5.26 | -1.05 | 0.88 | -4.27 | -7.57 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 235.01M | $ 342.40M | $ 142.94M | $ 170.37M | $ 291.58M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.13 | 0.11 | 0.15 | 0.10 | 0.00 |
| Debt-to-Equity Ratio | 0.17 | 0.14 | 0.28 | 0.12 | 0.00 |
| Debt-to-Capital Ratio | 0.14 | 0.12 | 0.22 | 0.11 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.23 | 1.23 | 1.94 | 1.19 | 1.02 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 | -36.23 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | -36.95 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 1.23 | 1.59 | 2.06 | 0.91 | 0.00 |
| Net Debt to EBITDA | 0.28 | -0.60 | -1.96 | 0.20 | 5.82 |
| Profitability Margins | |||||
| Gross Profit Margin | 83.89% | 100.00% | 100.00% | 0.00% | 0.00% |
| EBIT Margin | -561.84% | 31.54% | -2.45% | 0.00% | 0.00% |
| EBITDA Margin | -545.73% | 33.33% | -0.25% | 0.00% | 0.00% |
| Operating Profit Margin | -613.66% | 22.30% | -2.45% | 0.00% | 0.00% |
| Pretax Profit Margin | -561.84% | 31.54% | 9.34% | 0.00% | 0.00% |
| Net Profit Margin | -565.48% | 31.13% | -5.18% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | -565.48% | 31.13% | -5.18% | 0.00% | 0.00% |
| Net Income Per EBT | 100.65% | 98.71% | -55.45% | 100.00% | 100.00% |
| EBT Per EBIT | 91.56% | 141.42% | -381.28% | 97.29% | 100.06% |
| Return on Assets (ROA) | -38.09% | 12.47% | -1.42% | -37.54% | -16.73% |
| Return on Equity (ROE) | -46.96% | 15.31% | -2.76% | -44.51% | -17.13% |
| Return on Capital Employed (ROCE) | -44.20% | 9.66% | -1.02% | -42.27% | -17.09% |
| Return on Invested Capital (ROIC) | -43.69% | 9.39% | 0.55% | -40.78% | -17.09% |
| Return on Tangible Assets | -38.09% | 12.47% | -1.42% | -37.54% | -16.73% |
| Earnings Yield | -33.80% | 10.17% | -1.34% | -22.36% | -9.57% |
| Efficiency Ratios | |||||
| Receivables Turnover | 9.86 | 57.28 | 21.95 | 0.00 | 0.00 |
| Payables Turnover | 1.79 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.38 | 2.57 | 1.39 | 0.00 | 0.00 |
| Asset Turnover | 0.07 | 0.40 | 0.27 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.07 | 0.69 | 0.65 | 0.00 | 0.00 |
| Cash Conversion Cycle | -166.97 | 6.37 | 16.63 | 0.00 | 0.00 |
| Days of Sales Outstanding | 37.00 | 6.37 | 16.63 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 203.98 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 37.00 | 6.37 | 16.63 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -3.11 | -1.11 | 4.23 | -3.00 | -1.63 |
| Free Cash Flow Per Share | -3.13 | -1.20 | 4.06 | -3.09 | -1.78 |
| Dividend Paid and CapEx Coverage Ratio | -123.45 | -13.16 | 24.90 | -32.49 | -11.11 |
| Capital Expenditure Coverage Ratio | -123.45 | -13.16 | 24.90 | -32.49 | -11.11 |
| Operating Cash Flow Coverage Ratio | -2.52 | -0.70 | 2.05 | -3.62 | 0.00 |
| Operating Cash Flow to Sales Ratio | -5.06 | -0.20 | 1.08 | 0.00 | 0.00 |
| Free Cash Flow Yield | -30.46% | -6.93% | 26.91% | -22.85% | -10.37% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -2.96 | 9.82 | -74.60 | -4.47 | -10.45 |
| Price-to-Sales (P/S) Ratio | 16.73 | 3.06 | 3.87 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 1.39 | 1.50 | 2.06 | 1.99 | 1.79 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -3.28 | -14.43 | 3.72 | -4.38 | -9.64 |
| Price-to-Operating Cash Flow Ratio | -3.31 | -15.52 | 3.57 | -4.51 | -10.51 |
| Price-to-Earnings Growth (PEG) Ratio | 0.01 | -0.01 | 0.80 | -0.06 | -0.12 |
| Enterprise Value Multiple | -2.78 | 8.58 | -1555.63 | -4.24 | -4.87 |
| Enterprise Value | 385.84M | 603.02M | 499.36M | 403.86M | 243.50M |
| EV to EBITDA | -2.78 | 8.58 | -1555.63 | -4.24 | -4.87 |
| EV to Sales | 15.18 | 2.86 | 3.87 | 0.00 | 0.00 |
| EV to Free Cash Flow | -2.98 | -13.49 | 3.72 | -4.18 | -4.39 |
| EV to Operating Cash Flow | -3.00 | -14.51 | 3.57 | -4.31 | -4.79 |
| Tangible Book Value Per Share | 7.40 | 11.49 | 7.33 | 6.79 | 9.57 |
| Shareholders’ Equity Per Share | 7.40 | 11.49 | 7.33 | 6.79 | 9.57 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.01 | 0.01 | 1.55 | 0.00 | 0.00 |
| Revenue Per Share | 0.61 | 5.65 | 3.90 | 0.00 | 0.00 |
| Net Income Per Share | -3.47 | 1.76 | -0.20 | -3.02 | -1.64 |
| Tax Burden | 1.01 | 0.99 | -0.55 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.00 | -3.81 | 0.97 | 1.00 |
| Research & Development to Revenue | 5.60 | 0.59 | 0.77 | 0.00 | 0.00 |
| SG&A to Revenue | 1.61 | 0.18 | 0.25 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.77 | 0.08 | 0.10 | 0.00 | 0.00 |
| Income Quality | 0.89 | -0.63 | -20.91 | 0.99 | 0.99 |
Currency in USD
